+

WO1996032640A1 - Dosages immunologiques de haute precision dans lesquels on utilise des conjugues d'anticorps comprenant des matrices d'adn replicables - Google Patents

Dosages immunologiques de haute precision dans lesquels on utilise des conjugues d'anticorps comprenant des matrices d'adn replicables Download PDF

Info

Publication number
WO1996032640A1
WO1996032640A1 PCT/US1996/004494 US9604494W WO9632640A1 WO 1996032640 A1 WO1996032640 A1 WO 1996032640A1 US 9604494 W US9604494 W US 9604494W WO 9632640 A1 WO9632640 A1 WO 9632640A1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
variant
antibody
dna
variant dna
Prior art date
Application number
PCT/US1996/004494
Other languages
English (en)
Inventor
Richard A. Martinelli
Eddie Carroll, Iii
Original Assignee
Chiron Diagnostics Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Diagnostics Corporation filed Critical Chiron Diagnostics Corporation
Priority to JP8531046A priority Critical patent/JPH11503828A/ja
Priority to MX9707635A priority patent/MX9707635A/es
Priority to PL96322650A priority patent/PL322650A1/xx
Priority to DE69615673T priority patent/DE69615673D1/de
Priority to BR9604965A priority patent/BR9604965A/pt
Priority to EP96920100A priority patent/EP0819249B1/fr
Priority to AU58503/96A priority patent/AU5850396A/en
Priority to AT96920100T priority patent/ATE206520T1/de
Publication of WO1996032640A1 publication Critical patent/WO1996032640A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/682—Signal amplification
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/971—Capture of complex after antigen-antibody reaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/973—Simultaneous determination of more than one analyte
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/824—Immunological separation techniques
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/828—Protein A

Definitions

  • This invention is in the general field of immunochemistry. More specifically, the invention concerns sensitive immunoassays wherein antibodies conjugated to variant DNA templates are used with an appropriate RNA-dependent RNA polymerase, such as, QB replicase, in a novel signal amplification system that minimizes unwanted background signal.
  • an appropriate RNA- dependent RNA polymerase such as, QB replicase
  • Immunoassays for specific antigens are powerful tools for clinical diagnostics and for various molecular and cellular analyses.
  • the instant invention is directed at enhancing the sensitivity of immunoassays by employing variant DNA as an amplifiable reporter molecule.
  • the sensitivity of conventional immunoassays is in practice governed for a particular antibody-analyte interaction by the value of the equilibrium constant, which is normally referred to as the dissociation constant.
  • the equilibrium or dissociation constant reflects the amount of antibody-analyte complex formed at given concentrations of reactants. Typical values for the dissociation constant are found in the range of 10 *7 M to 10 "12 M. For example, at an antibody concentration equal to the dissociation constant, approximately 50% of a trace analyte will be complexed with the antibody at equilibrium.
  • Efforts to maximize sensitivity for immunoassays have included attaching labels, such as, enzymes, to antibodies such that the number of antibody-analyte complexes which can be detected is maximized.
  • the ultimate goal in such an approach is to be able to detect a single analyte-antibody complex.
  • An article by Chu et al., ucleic Acids Research. 3.4: 5591 (1986)] concerns the use of midivariant RNA as an amplifiable reporter to enhance the sensitivity of bioassays.
  • Midivariant RNA serves as a template for its own replication which is catalyzed by QB replicase. [Miele et al., J. Mol. Biol..
  • variant DNAs rather than midivariant RNA
  • templates for RNA synthesis with appropriate RNA-dependent RNA polymerases, such as, QB replicase.
  • variant DNA templates such as, nanovariant and midivariant DNA templates
  • QB replicase RNA-dependent RNA polymerases
  • variant DNA templates such as, nanovariant and midivariant DNA templates
  • the immunoassay methodology of this invention employs variant DNA as an amplifiable label conjugated to an antibody or biologically active antibody fragment.
  • the advantages for the use of the amplifiable DNA templates of this invention over their RNA counterparts as labels for antibodies are several.
  • DNA is inherently more stable than RNA. Also, as indicated above, the relative inefficiency of the replication of the DNA templates can be used effectively to mask the potential signal generated from non-specific binding of the antibody conjugates, and thus, the assays of this invention should be more sensitive than assays employing corresponding RNA template conjugates.
  • This invention in one aspect concerns immunoassay methods that use an antibody-variant DNA conjugate as a tracer antibody, wherein the variant DNA is a substrate for an RNA- dependent RNA polymerase.
  • the use of said conjugate provides a novel signal amplification system for immunoassays.
  • the antibody of the conjugate can be directed to either an analyte under assay or to an anti-analyte antibody used in an immunoassay.
  • the variant DNA template, bound to the analyte is transcribed, and the RNA transcript is replicated by contact with an appropriate amount of an RNA-dependent RNA polymerase, whose substrate is the variant DNA, in the presence of ribonucleotides.
  • the detection of RNA replication products produced in the assay indicates the presence of the analyte under assay.
  • RNA replication products can also be quantitated, and the quantity of the replication products can be correlated with the quantity of the analyte assayed.
  • the immunoassay methods of this invention can be used for detecting or, for detecting and quantitating analyte in a test sample.
  • immunoassay methods of this invention can be used to detect, or to detect and quantitate, simultaneously two or more analytes in a test sample.
  • Such methods comprise the use of two or more different antibody-variant DNA conjugates, wherein the variant DNA of different conjugates comprise different DNA sequences inserted therein, and wherein said inserted DNA sequences do not correspond to naturally occurring variant RNA sequences that are templates for RNA- dependent RNA polymerases.
  • Those DNA sequences are preferably non-variant DNA.
  • the inserted DNA sequences are preferably inserted at a position in the variant DNA other than within 10 bases from the 3' end, more preferably other than within 20 bases from the 3' end.
  • the antibodies of different conjugates that is, antibodies conjugated to variant DNA containing different inserted DNA sequences
  • antibodies that are conjugated to variant DNA containing the same inserted DNA sequence are specific for the same analyte.
  • Nucleic acid probes, preferably RNA probes, that are complementary to the different variant RNA replication products are preferably used to detect, or, to detect and quantitate the RNA replication products of such immunoassay methods. Probes complementary to the same variant RNA replication products are similarly labeled, whereas probes complementary to different variant RNA replication products are differently labeled.
  • Immunoassay reagents comprising the antibody-variant DNA conjugates of this invention are described below, as well as representative methods of preparing such conjugates.
  • Exemplary immunoassay reagents include those wherein the variant DNA of said antibody-variant DNA conjugates is conjugated to the antibody of said conjugates through an avidin-biotin, preferably streptavidin-biotin, bridge, via
  • exemplary regents can include variant DNA conjugated to avidin and/or Protein A.
  • Different DNA sequences can be inserted in the variant DNA of the immunoassay reagents of this invention to provide reagents that generate individual amplifiable signals.
  • Reagents containing such variant DNA with inserted DNA sequences can be used in methods of this invention to detect, or to detect and quantitate, simultaneously two or more analytes in a test sample.
  • Immunoassay test kits comprise immunoassay regents of this invention and an apropriate RNA-dependent RNA polymerase, wherein the variant DNA of the reagents is a substrate for the polymerase.
  • Such test kits can further comprise a solid phase to which an anti-analyte antibody or a receptor for the analyte under assay is attached.
  • Other embodiments of such immunoassay test kits can comprise variant DNA conjugated to avidin, preferably streptavidin, and/or Protein A.
  • RNA ribonucleic acid SMCC - succinimidyl 4-(N-maleimido-methyl) cyclohexane-1- carboxylate SPDP - N-succinimidyl-3-(2-pyridylthio)-propionate UTP - uridine triphosphate ⁇ M - micromolar ⁇ g - microgram
  • aspects of this invention revolve around antibody- variant DNA conjugates that are immunoassay reagents.
  • the conjugates are components of an immunoassay signal amplification system.
  • the signal for an analyte molecule needs to be amplified, so that the signal is visualizable and thus detectable.
  • the instant invention provides such a signal amplification system.
  • the system can produce an amplified signal representative of the number of analyte molecules in a sample that is assayed by methods of this invention.
  • the variant DNA of the conjugates when bound to an immunocomplex according to this invention is transcribed to RNA, and then the RNA transcripts are replicated, by contact with an appropriate RNA-dependent RNA polymerase in the presence of ribonucleotides, resulting in RNA replication products.
  • RNA variant molecules can be produced.
  • Those RNA replication products are rendered visualizable by an appropriate means, such as by labeling with a radionuclide, fluorescer, chemiluminescer, or enzyme or by staining with an intercalating dye, among other methods (as discussed infra) .
  • Examples 1-3 demonstrate some representative methods of preparing the antibody-variant DNA conjugates of this invention.
  • Example 4 demonstrates the ability of variant DNA conjugated to an antibody to serve as a template for an RNA-dependent RNA polymerase to synthesize RNA.
  • nanovariant DNA conjugated to antibodies via the representative cross-linking reagent SPDP retains its capability to serve as a template for QB replicase catalyzed synthesis of nanovariant RNA.
  • representative antibody-variant DNA conjugates of this invention may be used for immmunoassays of enhanced sensitivity.
  • the overall antibody concentration is chosen so that the amount of conjugated antibody non-specifically bound and capable of amplification by a RNA-dependent RNA polymerase, such as, QB replicase, is approximately 1000 to 10,000 molecules.
  • a RNA-dependent RNA polymerase such as, QB replicase
  • the current replication sensitivity of a nanovariant DNA or midivariant DNA template in solution has been found by the inventors to be approximately 10,000 molecules. Since levels of DNA template below that level do not appear to yield detectable levels of RNA synthesis, no background signal may be expected from that level of non ⁇ specific binding. Thus 1000 to 10,000 molecules would be the theoretical limit of sensitivity for the immunoassays of this invention.
  • a specific immunoassay can be optimized by methods known to those of skill in the art.
  • binding to a second reagent such as, a second antibody attached to a solid phase would take place as in conventional immunoassay formats.
  • a solid phase reagent facilitates the separation of the bound and unbound antibody-conjugate.
  • a particularly prepared solid phase comprises a paramagnetic particle (PMP) [Ciba Corning Diagnostics Corp.; Medfield, Massachusetts (USA) ] .
  • PMP paramagnetic particle
  • capture antibody or receptor to the analyte under assay are attached to such PMPs, captured immunocomplexes can be separated from unbound antibody-variant DNA conjugates by applying a magnetic field. After separation and wash as in conventional immunoassays, the solid phase with the adsorbed antibody conjugate is incubated with an RNA-dependent RNA polymerase, such as, QB replicase to provide the amplified signal.
  • an RNA-dependent RNA polymerase such as, QB replicase
  • the variant RNA such as nanovariant RNA or midivariant RNA, synthesized in that amplification step is produced in sufficient quantities to render it detectable by a variety of methods, radioactive or non-radioactive, as are conventionally used.
  • a preferred embodiment for practicing this invention would include, for example, incubating a test sample containing the analyte to be detected, or, to be detected and quantitated, with an antibody which binds specifically to the analyte and is conjugated with nanovariant or midivariant DNA for an appropriate amount of time. Another preferred embodiment would be to mix a small amount of such an antibody- variant DNA conjugate according to this invention with unconjugated antibody that is specific for the analyte to be determined.
  • an exemplary immunoassay method of this invention for detecting, or, for detecting and quantitating an analyte in a test sample comprises the steps of:
  • step (e) determining whether any variant RNA is replicated in step (d) and correlating the presence of RNA replication products with the presence of analyte; or detecting and quantitating variant RNA replicated in step (d) , and correlating the quantity of said RNA replication products with the quantity of analyte.
  • Such a method can further comprise before step (c) or simultaneously with step (c) , contacting said test sample with a receptor for said analyte, or with an additional anti- analyte antibody which is directed to a different epitopic site on said analyte than to that which said second antibody, if present, is directed, or than to that which the corijugate antibody is directed, if said conjugate antibody is directed to an epitopic site on said analyte.
  • analyte receptor or said anti-analyte antibody of such preferred embodiments can be immobilized upon a solid phase.
  • exemplary of an analyte receptor are estrogen receptors, progesterone receptors, growth factor receptors, among many others.
  • Another preferred embodiment is that wherein two or more analytes in a test sample are detected, or detected and quantitated simultaneously.
  • Two or more different antibody- variant DNA conjugates are used in such an embodiment, wherein the variant DNA of different conjugates comprise different DNA sequences inserted therein, preferably at a position other than within 10 bases from the 3' end of the variant DNA, more preferably other than within 20 bases from the 3' end.
  • Such inserted DNA sequences are sequences whose RNA counterparts do not naturally occur in variant RNA templates that are substrates for RNA-dependent RNA polymerases, such as, QB replicase. More preferably, such inserted sequences are non-vari nt DNA. [See. Martinelli et al., European Patent Application Publication No.
  • the lengths of such inserted DNA sequences can be from about 10 nucleotides to about 120 nucleotides.
  • the variant DNA is nanovariant or midivariant DNA, wherein the lengths of the inserted DNA sequences are preferably from about 10 nucleotides to about 50 nucleotides, more preferably from about 10 nucleotides to about 30 nucleotides.
  • Midivariant DNA is particularly preferred according to this invention for inserting therein different DNA sequences.
  • Inserted DNA sequences that have no RNA counterparts naturally occuring in midivariant RNA, which is a template for QB replicase, having lengths of from about 10 to about 120 bases, have been found to be transcribed and replicated successfully from midivariant DNA.
  • Such sequences are preferably inserted in a midivariant DNA template at a position about in the middle of the midivariant DNA, or at a position about one quarter of the length of the midivariant DNA from the 5' end, that is, from about 55 to 70 bases from the 5' end.
  • such inserted DNA sequences be inserted at a position in the positive strand of the midivariant DNA [MDV-1 (+) DNA] at about nucleotides 130 to 131, or at about nucleotides 61 to 64, more preferably at nucleotide 63.
  • an embodiment of such assays for detecting, or for detecting and quantitating, simultaneously two or more different analytes in a test sample is that wherein the antibodies conjugated to variant DNA containing different inserted DNA sequences are specific for different analytes, whereas antibodies conjugated to variant DNA containing the same inserted DNA sequences are specific for the same analyte.
  • antibodies conjugated to variant DNA containing different inserted DNA sequences are specific for different analytes
  • antibodies conjugated to variant DNA containing the same inserted DNA sequences are specific for the same analyte.
  • the different variant DNAs when bound respectively in immunocomplexes to different analytes, are transcribed, and the RNA transcripts are replicated, by contact with an appropriate RNA-dependent RNA polymerase.
  • the different variant RNA replication products can be detected by hybridization to differently labeled nucleic acid probes, preferably RNA probes.
  • the probes are complementary to the RNA counterparts of the DNA sequences inserted within the variant DNA of the conjugates.
  • the probes hybridize under standard hybridization conditions, to the variant RNA replication products. Varying conditions of hybridization may be desired, depending on, for example, the specific immunoassay envisioned, the number of analytes to be detected or the selectivity of the probe towards the target RNA replication product sequence. Where a high degree of selectivity is desired, one may employ relatively stringent hybridization conditions, such as, relatively low salt and/or high temperature conditions. Under such conditions, relatively little mismatch between the probe and the target sequence is tolerated. Less stringent conditions may usually be desired when optimizing conditions for a specific immunoassay.
  • a representative embodiment of a method according to this invention for detecting, or for detecting and quantitating, two or more analytes simultaneously in a test sample comprises performing the exemplary immunoassay, outlined above in relation to a single analyte, simultaneously with two or more different antibody-variant DNA conjugates, wherein the antibody-variant DNA conjugates differ in that the variant DNA of the different conjugates comprise different DNA sequences inserted therein.
  • the DNA sequences inserted in the variant DNA are the same when conjugated to antibodies having similar binding specificities, whereas the inserted DNA sequences are different in variant DNAs conjugated to antibodies having different binding specificities.
  • an exemplary immunoassay method of this invention for detecting, or detecting and quantitating, two or more analytes simultaneously in a test sample comprises the steps of:
  • variant DNA of different conjugates comprises different DNA sequences inserted therein; wherein the antibodies conjugated to variant DNA containing different inserted DNA sequences are specific for different analytes, whereas the antibodies conjugated to variant DNA containing the same inserted DNA sequence are specific for the same analyte; and wherein the variant DNA of said conjugates is a substrate for an RNA-dependent RNA polymerase;
  • step (e) determining whether any variant RNA is replicated in step (d) , and, if so, determining from which variant DNA template or templates, said variant RNA was transcribed, and correlating the presence of RNA replication products generated from a certain variant DNA template with the presence of the corresponding analyte, that is, the analyte, for which the antibody to which that certain variant DNA is conjugated is specific; or determining from which variant DNA template or templates, said variant RNA replicated in step (d) was transcribed, quantitating each of the different variant RNA replication products, and correlating the quantity of each of the RNA replication products with the quantity of each corresponding analyte.
  • the different variant RNAs replicated from the different variant DNA templates are preferably detected in step (e) by employing two or more differently labeled nucleic acid probes that are complementary to the different variant RNAs that are replicated, and wherein the probes that are complementary to one type of replicated variant RNA are similarly labeled.
  • the differently labeled nucleic acid probes are RNA probes, and are complementary respectively to the different DNA sequences inserted in said different variant DNAs.
  • An antibody-variant DNA conjugate of this invention can be a universal immunoassay reagent or can be directed against a specific analyte.
  • Embodiments wherein the antibody- variant DNA conjugate is a universal type reagent may be preferred for certain immunoassays.
  • an exemplary universal reagent would be that wherein the antibody of the conjugate is directed against antibodies that originated by immunizing a mammal of a different genus, than that from which the conjugate antibody originated.
  • the antibody of the conjugate could be a goat anti-mouse antibody, and thus be useful as a component of a signal amplification system for any immunoassay employing mouse antibodies.
  • antibodies are antibodies functionally equivalent to such antibodies, as represented by a goat anti- mouse antibody, as, for example, those that are genetically engineered or otherwise prepared, and biologically active antibody fragments.
  • the antibody-variant DNA conjugate can be considered to be a universal type of immunoassay reagent is that wherein the variant DNA is linked to avidin, and biotinylated anti-analyte antibodies are used.
  • the universal immunoassay reagent is actually the variant DNA linked to avidin, preferably the variant DNA linked to streptavidin.
  • the variant DNA-antibody conjugate in that embodiment is prepared during the immunoassay procedure.
  • RNA-dependent RNA polymerases are herein sometimes referred to as "replicases.” It is generally considered known in the art is that such replicases are enzymes that replicate, that is, reproduce, RNA transcripts and their complements so as to multiply copies thereof. When a replicase is present during the process of transcription, it can be forseen that the multiple transcripts that are produced during transcription can themselves undergo replication so as to increase exponentially the amount of RNA transcript product.
  • a replicase functions to replicate exponentially an RNA transcript as long as the replicase is in molar excess over the RNA strands produced.
  • the variant DNA of the conjugate of this invention thus serves as a template for the synthesis of a complementary RNA strand. After N rounds of replication, there will be 2 N strands produced for each initial template strand.
  • RNA replicases have been isolated from Escherichia coli RNA phages [Lewin, B. in Gene Expression. 3: 790-824 (John Wiley & Sons; 1977)]; from plant RNA viruses [Miller et al., J. Mol. Biol.. 187: 537 (1986)], and as a secondary catalytic activity present in T7 RNA polymerase [Konarska and Sharp, Cell. 57: 427 (1989)].
  • QB replicase is the best characterized of the RNA replicases.
  • QB replicase is a particularly preferred replicase for use in the immunoassay methods of this invention. [See, Miele et al., "Autocatalytic Replication of a Recombinant RNA," J. Mol.
  • QB replicase can be isolated from bacteriophage QB-infected Escherichia coli. by the procedure of Eoyang and August in Procedures in Nucleic Acid Research. 2: 829-839, [eds. Cantoni and Davies (Harper and Row, N.Y. ; 1971) ].
  • the QB virus is an RNA phage of approximately 4400 ribonucleotides. [See. Blumenthal in The Enzyme. Vol. XV. Part B, p. 267, ed. P.D. Boyer (Academic Press, N.Y.; 1982).] Although QB replicase replicates only QB RNA and not other viral RNA sequences, shorter, RNA sequences can also serve as templates for replication. Those shorter templates include "nanovariant" RNA which is 90 ribonucleotides in length and "midivariant" RNA which is 220 ribonucleotides in length.
  • RNA-dependent RNA-polymerases that can be used as part of the signal amplification system of the immunoassays of this invention include the RNA phage replicases SP, MS2 and GA. [See. Mills et al., J. Mol. Biol..
  • Another replicase that may be useful in the methods of this invention is the Brome Mosaic Virus replicase. [March et al., Positive Strand RNA Viruses (Alan R. Liss; N.Y.; 1987).] Other replicases and their associated substrates, can be found in Miyake et al., PNAS (USA), 68: 2022 (1971).
  • Variant DNAs correspond to variant RNAs which are substrates for replicases.
  • midivariant DNA corresponds to midivariant RNA.
  • Preferred variant DNAs according to this invention are nanovariant, midivariant, microvariant and minivariant DNAs; more preferred are nanovariant and midivariant DNAs, most preferably those that are substrates for QB replicase; and further preferred are nanovariant DNAs that are substrates for QB replicase.
  • antibodies is defined herein to include not only whole antibodies but also biologically active fragments of antibodies, preferably fragments containing the antigen binding regions. Such antibodies may be prepared by conventional methodology and/or by genetic engineering. Antibody fragments may be genetically engineered, preferably from the variable regions of the light and/or heavy chains (V H and V L ) , including the hypervariable regions, and still more preferably from both the V H and V L regions.
  • V H and V L variable regions of the light and/or heavy chains
  • antibodies as used herein comprehends polyclonal and monoclonal antibodies and biologically active fragments thereof including among other possibilities “univalent” antibodies [Glennie et al., Nature, 295: 712 (1982)]; Fab proteins including Fab' and F(ab') 2 fragments whether covalently or non-covalently aggregated; light or heavy chains alone, preferably variable heavy and light chain regions (V H and V L regions) , and more preferably including the hypervariable regions [otherwise known as the complementarity determining regions (CDRs) of said V H and V L regions] ; F c proteins; "hybrid” antibodies capable of binding more than one antigen; constant-variable region chimeras; "composite” immunoglobulins with heavy and light chains of different origins; "altered” antibodies with improved specificity and other characteristics as prepared by standard recombinant techniques and also by oligonucleotide-directed mutagenesis techniques [Dalbadie-M
  • Fab fragments are particularly preferred fragments in accordance with this invention to avoid non ⁇ specific binding.
  • Antibodies for use in the instant invention can be genetically engineered.
  • Examples 1 and 2 Two general approaches to prepare antibody-variant DNA conjugates of this invention are shown in Examples 1 and 2 below.
  • a derivative of nanovariant DNA such as PM444 (SEQ. ID. NO.: 1) [Promega; Madison, WI (USA)]
  • a primary amine was conjugated to mildly reduced antibodies via a heterobifunctional group, such as SPDP.
  • an amino- derivatized nanovariant DNA can be coupled to an antibody's amine groups by using a heterobifunctional group, such as SPDP.
  • RNA replicases such as, QB replicase, initiate product strand synthesis at the 3' end.
  • Further preferred methods for preparing such an amino- derivatized variant DNA comprise the use of a DNA synthesizer.
  • Other coupling agents preferably heterobifunctional linking agents, known to those in the art, include m-maleimidobenzoyl N-hydroxysuccinimide ester [Kitagawa, T. in Enzvme Immunoassay (eds.
  • a variant DNA preferably nanovariant or midivariant DNA
  • avidin preferably streptavidin
  • biotin could be attached to the 5' terminus of midivariant or nanovariant DNA via a disulfide linker, and the biotinylated DNA could be combined with avidin to form a DNA-biotin-avidin adduct, which then could be conjugated to biotinylated antibodies.
  • Other methods of attaching avidin to variant DNA are known to those in the art such as methods employing Protein A. [See, for example, Sano et al., Science 258: 120 (2 Oct. 1992).]
  • RNA replication products produced by the immunoassay methods of this invention there are many conventional means to detect the RNA replication products produced by the immunoassay methods of this invention. They include the incorporation of radioactive labels, e.g. Harper et al., Chromosoma. 83: 431-439 (1984); direct attachment of fluorochromes or enzymes, e.g. Smith et al., Nuc. Acids Res.. 13: 2399-2412 (1985), and Connolly et al., Nuc. Acids Res.. 13: 4485-4502 (1985); and various chemical modifications of nucleic acids that render them detectable immunochemically or by other affinity reactions, e.g.
  • Exemplary detection means include the use of labels, such as, radionuclides, enzymes, coenzymes, fluorescers, chemiluminescers, chromogens, enzyme substrates, enzyme co-factors, enzyme inhibitors, free radicals, particles, dyes and the like.
  • exemplary labeling means include those wherein the RNA replication products are biotinylated, modified with N-acetoxy-N-2-acetylaminofluorene, modified with fluorescein isothiocyanate, sulfonated, digoxigeninated, modified to contain T-T dimers or stained with an intercalating dye.
  • the RNA replication products are detected by chemiluminescent methodology. See U.S. Patent No. 4,745,181. The use of acridinium ester as a chemiluminescer is particularly preferred.
  • Example 4 details a representative detection means wherein radioactively labeled ribonucleotides ( 3 P-CTPs) are incorporated in the RNA replication products.
  • radioactively labeled ribonucleotides 3 P-CTPs
  • fluorochromes, enzymes or other labels may be incorporated in the replication products.
  • Another exemplary method for incorporating fluorescent nucleotides in replicated RNA is shown in Cosstick et al., Nuc. Acids Res.. 12: 1791 (1984).
  • electrophoretic means such as, the use of polyacrylamide gel electrophoresis, could be used to detect and/or quantitate the RNA replication products. [See, for example, Sano et al., Science. 258: 120 (2 October 1992).]
  • Another detection methodology incorporates the use of optical devices to propagate radiation by "total internal reflection” to generate an evanescent wave at the interface of the device and a test medium having a lower index of refraction. See Harrick, N.J. , Internal Reflection Spectroscopy (Harrick Scientific Corp; N.Y; 3rd printing 1987); and U.S. Patent No. 4,880,752.
  • the signal generated from the replication products indicates the presence of the analyte under assay. That signal may also be used to quantitate the amount of the analyte present in the assay by methods known to those of skill in the art.
  • the amount of time it takes to synthesize a particular, though arbitrary, mass of amplified RNA from the variant DNA templates is directly related to the logarithm of the number of DNA molecules present at the start of the assay (time zero) .
  • the amount of amplified RNA can be measured, for example, by the florescence of an intercalating dye, such as, ethidium bromide.
  • an intercalating dye such as, ethidium bromide.
  • the signal amplification system of this invention can be used in a variety of immunoassay formats, such as, sandwich assays, competition assays, bridge immunoassays, among other formats well known to those of skill in the art.
  • immunoassay formats such as, sandwich assays, competition assays, bridge immunoassays, among other formats well known to those of skill in the art.
  • Example l The nanovariant DNA used in the examples described herein is PM444 [Promega].
  • PM444 has the following nucleotide sequence:
  • a primary amine group was introduced into PM444 at its 3' terminus using terminal transferase with either aminohexyl-ATP or a combination of aminohexyl-ATP and dATP.
  • the product of this reaction was labeled at its 5' terminus with 32 P with polynucleotide kinase and gamma 32 P-ATP.
  • RNA-DNA hybrid 100 nM was reduced with dithiothreitol (DTT) (20 M) at room temperature for 30 min in 50 mM NaP0 4 , 150 mM NaCL, 1 mM EDTA (PBSE) .
  • DTT dithiothreitol
  • the reduced antibody was desalted on Sephadex G-25 in PBSE.
  • the SPDP-derivatized oligomer was incubated with the reduced antibody at room temperature overnight.
  • the antibody-DNA conjugate formed in this reaction was purified by affinity chromatography on Affigel Protein A [Biorad; Hercules, CA (USA)].
  • 32 P labeled oligomer which bound to the column did so by virtue of its conjugation to the antibody.
  • Bound material was eluted from the column with 0.1 M sodium citrate, pH 3 and neutralized by the addition of 1 M Tris, pH 9. The fractions containing 32 P were identified by liquid scintillation counting.
  • Example 2 Anti-RNA-DNA hybrid monoclonal antibody (15 ⁇ M) and SPDP (100 ⁇ M) were reacted at room temperature for 1 hr.
  • the derivatized antibody was desalted on Sephadex G25.
  • the amino-oligomer (10 nM) that is, the a ino derivatized PM444 as prepared in Example 1, was also incubated with SPDP (100 ⁇ M) at room temperature for 1 hr. To that solution, DTT was added to give a final concentration of 0.1 M, and reduction proceeded for 10 minutes.
  • the thiol- derivatized oligomer resulting from the reaction was desalted on Sephadex G-25.
  • the oligomer was then incubated with the SPDP- derivatized antibody at room temperature overnight.
  • the antibody-oligomer conjugate formed was purified by affinity chromatography on Affigel Protein A as described above in Example 1.
  • Example 3 A version of PM444 containing an amine group at its 5' terminus was prepared, and labeled at its 3' terminus with 32 P-dideoxy-ATP with terminal transferase. That version of PM444, called PM653 [Promega] , was also coupled to antibody via SPDP by using each of the methods described above in Examples 1 and 2.
  • Example 4 The ability of antibody-conjugated variant DNA to serve as a template for QB replicase catalyzed synthesis of variant RNA was examined.
  • exemplary of such antibody- conjugated variant DNA is the antibody-conjugated nanovariant DNA, that is, the antibody-PM444 conjugates, prepared as described in Examples 1 and 2. The antibody-PM444 conjugates were incubated with
  • RNA synthesis was due to contamination by nanovariant RNA
  • either no antibody conjugate was added to the replicase reactions, or the antibody conjugates were digested with deoxyribonuclease [DNAse; Promega] at 37°C for 1 hr prior to addition to the replicase reaction.
  • DNAse deoxyribonuclease
  • Antibody-PM4 4 0.62 Antibody-PM444 + DNAse 0.11 PM444 1.65 PM444 + DNAse 0.07
  • MOLECULE TYPE DNA (nanovariant)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Cette invention concerne un nouveau système d'amplification des signaux pour des dosages immunologiques qui minimise les signaux non spécifiques. On décrit des procédés de dosage immunologique, des réactifs et des kits de test qui permettent de produire des dosages immunologiques plus précis. Les réactifs comprennent des conjugés d'anticorps-ADN variant dans lesquels l'ADN variant est un substrat destiné à une polymérase d'ARN dépendant de l'ARN telle que la réplicase QB. Les procédés de dosage immunologique utilisés pour détecter ou bien pour détecter et quantifier un analyte dans des échantillons de test comprennent la transcription de l'ADN variant desdits conjugués d'anticorps-ADN qui sont liés à l'analyte, sur l'ARN, puis la réplication des transcriptions d'ARN, la présence ou la quantité des produits de réplication de l'ARN variant pouvant être corrélée à la présence ou à la quantité d'analyte présent dans les échantillons de test. On décrit également des procédés qui permettent de détecter ou bien de détecter et de quantifier simultanément deux ou plusieurs analytes dans un échantillon de test.
PCT/US1996/004494 1995-04-04 1996-04-01 Dosages immunologiques de haute precision dans lesquels on utilise des conjugues d'anticorps comprenant des matrices d'adn replicables WO1996032640A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP8531046A JPH11503828A (ja) 1995-04-04 1996-04-01 複製可能なｄｎａテンプレートと抗体との接合体を用いた高感度イムノアッセイ
MX9707635A MX9707635A (es) 1995-04-04 1996-04-01 Inmunoanalisis sensibles que utilizan conjugados anticuerpos con moldes de adn replicables.
PL96322650A PL322650A1 (en) 1995-04-04 1996-04-01 Sensitive tests using conjugatesof antibodies with repeatable dna matrices
DE69615673T DE69615673D1 (de) 1995-04-04 1996-04-01 Empfindlicher immuntest, der antikörperkonjugate mit replizierbaren dns-matrizen verwendet
BR9604965A BR9604965A (pt) 1995-04-04 1996-04-01 Testes imunológicos sensíveis utilizando conjugados de anticorpos com matrizes replicáveis de dna
EP96920100A EP0819249B1 (fr) 1995-04-04 1996-04-01 Dosages immunologiques de haute precision dans lesquels on utilise des conjugues d'anticorps comprenant des matrices d'adn replicables
AU58503/96A AU5850396A (en) 1995-04-04 1996-04-01 Sensitive immunoassays utilizing antibody conjugates with replicable DNA templates
AT96920100T ATE206520T1 (de) 1995-04-04 1996-04-01 Empfindlicher immuntest, der antikörperkonjugate mit replizierbaren dns-matrizen verwendet

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/416,571 US6083689A (en) 1990-10-16 1995-04-04 Sensitive immunoassays utilizing antibody conjugates with replicable DNA templates
US08/416,571 1995-04-04

Publications (1)

Publication Number Publication Date
WO1996032640A1 true WO1996032640A1 (fr) 1996-10-17

Family

ID=23650484

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004494 WO1996032640A1 (fr) 1995-04-04 1996-04-01 Dosages immunologiques de haute precision dans lesquels on utilise des conjugues d'anticorps comprenant des matrices d'adn replicables

Country Status (12)

Country Link
US (1) US6083689A (fr)
EP (1) EP0819249B1 (fr)
JP (1) JPH11503828A (fr)
KR (1) KR19980703574A (fr)
AT (1) ATE206520T1 (fr)
AU (1) AU5850396A (fr)
BR (1) BR9604965A (fr)
CA (1) CA2216466A1 (fr)
DE (1) DE69615673D1 (fr)
MX (1) MX9707635A (fr)
PL (1) PL322650A1 (fr)
WO (1) WO1996032640A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813064A1 (fr) * 1996-06-10 1997-12-17 Bayer Corporation Méthode d'amplification du signal de réponse à un immuno-essai sandwich
DE19959857C1 (de) * 1999-12-10 2001-06-28 Aventis Res & Tech Gmbh & Co Testsystem zum Nachweis von Analyten sowie ein Verfahren zur Herstellung und Verwendung
DE10041766A1 (de) * 2000-08-25 2002-03-14 Friz Biochem Gmbh Verfahren zur Markierung chemischer Substanzen
GB2375822A (en) * 2000-12-05 2002-11-27 Norchip As Immunoassay using nucleic acid amplification and real-time measurement
WO2003048388A3 (fr) * 2001-12-07 2003-09-25 Univ Liverpool Immuno-dosage utilisant l'amplification en chaine de par polymerase
WO2005003394A3 (fr) * 2003-06-27 2005-07-28 Nanosphere Inc Detection d'analytes cible a base de codes a barres biochimiques
WO2006078289A3 (fr) * 2004-05-12 2007-02-08 Nanosphere Inc Detection d'analytes cibles fondee sur des codes a barres biologiques
WO2022231730A3 (fr) * 2021-03-22 2023-01-26 Northwestern University Stratégie de synthèse pour polymériser une protéine en polymères définis au plan moléculaire

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001061349A1 (fr) * 2000-02-18 2001-08-23 The University Of Tennessee Research Corporation Detection de depot microbien et reponse immunitaire au niveau de la membrane basale
US7846733B2 (en) 2000-06-26 2010-12-07 Nugen Technologies, Inc. Methods and compositions for transcription-based nucleic acid amplification
ATE475720T1 (de) 2000-12-13 2010-08-15 Nugen Technologies Inc Methoden und zusammensetzungen zur generierung einer vielzahl von kopien von nukleinsäuresequenzen und methoden zur detektion derselben
IL153504A0 (en) 2001-03-09 2003-07-06 Nugen Technologies Inc Methods and compositions for amplification of rna sequences
US7018795B2 (en) * 2001-03-23 2006-03-28 Fuji Photo Film Co., Ltd. Hybridization probe and target nucleic acid detecting kit, target nucleic acid detecting apparatus and target nucleic acid detecting method using the same
US20020168291A1 (en) * 2001-03-23 2002-11-14 Fuji Photo Film Co., Ltd. Agent for health inspection and health inspection apparatus using the same
US20020168667A1 (en) * 2001-03-23 2002-11-14 Fuji Photo Film Co., Ltd. Antigen detecting agent and antigen detecting kit, antigen detecting apparatus and antigen detecting method using the same
US20030003476A1 (en) * 2001-03-23 2003-01-02 Fuji Photo Film Co., Ltd. Waste water inspecting agent and waste water inspecting apparatus using the same
US20020168756A1 (en) 2001-03-23 2002-11-14 Fuji Photo Film Co., Ltd. Particle size variable reactor
US7077982B2 (en) * 2001-03-23 2006-07-18 Fuji Photo Film Co., Ltd. Molecular electric wire, molecular electric wire circuit using the same and process for producing the molecular electric wire circuit
JP3691428B2 (ja) * 2001-11-12 2005-09-07 三菱電機株式会社 飛行体展示装置
US20030175828A1 (en) * 2002-03-15 2003-09-18 Lazar James G. Signal amplification by Hybrid Capture
US20030179381A1 (en) * 2002-03-18 2003-09-25 Fuji Photo Film Co., Ltd. Sensor, color sensor and apparatus for inspection using the same
JP2005533256A (ja) * 2002-07-17 2005-11-04 ユー．エス． ジェノミクス， インコーポレイテッド キメラタグを用いるポリマーを分析するための方法と組成物
JP4294946B2 (ja) * 2002-12-13 2009-07-15 富士フイルム株式会社 標的検出装置及び標的検出方法並びに標的検出用基材
US7076127B2 (en) * 2003-01-14 2006-07-11 Fuji Photo Film Co., Ltd. Optical switch and safety apparatus using the same
JP2006523465A (ja) 2003-04-14 2006-10-19 ニューゲン テクノロジーズ， インコーポレイテッド ランダムにプライミングされる複合プライマーを用いる大規模増幅
CN101410530B (zh) 2003-04-18 2013-03-27 贝克顿·迪金森公司 免疫-扩增
US20050214805A1 (en) * 2003-11-10 2005-09-29 Q-Rna, Inc. Methods of detection employing immuno-Q-Amp technology
US20060199194A1 (en) * 2003-11-10 2006-09-07 Q-Rna, Inc. Methods of detection using immuno-Q-Amp technology
WO2005067692A2 (fr) * 2004-01-13 2005-07-28 U.S. Genomics, Inc. Detection et quantification d'analytes en solution a l'aide de polymeres
US20050221408A1 (en) * 2004-03-19 2005-10-06 U.S. Genomics, Inc. Compositions and methods for detection of single molecules
US20060204999A1 (en) * 2005-03-14 2006-09-14 Stephen Macevicz Detecting molecular complexes
WO2007030759A2 (fr) 2005-09-07 2007-03-15 Nugen Technologies, Inc. Procedure d'amplication d'acide nucleique amelioree
US20100035247A1 (en) * 2005-11-04 2010-02-11 U.S. Genomics, Inc. Heterogeneous Assay of Analytes in Solution Using Polymers
WO2009009127A2 (fr) * 2007-07-12 2009-01-15 U.S. Genomics, Inc. Procédé et système de transfert et/ou de concentration d'un échantillon
US8034568B2 (en) * 2008-02-12 2011-10-11 Nugen Technologies, Inc. Isothermal nucleic acid amplification methods and compositions
WO2009117698A2 (fr) 2008-03-21 2009-09-24 Nugen Technologies, Inc. Procédés d'amplification d'arn en présence d'adn
KR101029343B1 (ko) * 2009-07-30 2011-04-13 한국과학기술연구원 면역분석 기반의 항원 검출용 키트 및 항원 검출 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957858A (en) * 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
EP0481704A1 (fr) * 1990-10-16 1992-04-22 Ciba Corning Diagnostics Corp. L'amplification de matrices d'ADN de midivariant
US5395752A (en) * 1993-03-19 1995-03-07 Ciba Corning Diagnostics Corp. Long emission wavelength chemiluminescent compounds and their use in test assays
US5451505A (en) * 1989-05-22 1995-09-19 Hoffmann-La Roche Inc. Methods for tagging and tracing materials with nucleic acids

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US4883750A (en) * 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US5242794A (en) * 1984-12-13 1993-09-07 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
EP0446305B1 (fr) * 1988-12-05 1996-05-08 The Salk Institute For Biological Studies Systemes d'amplification/detection d'acides nucleiques
US5112734A (en) * 1989-05-26 1992-05-12 Gene-Trak Systems Target-dependent synthesis of an artificial gene for the synthesis of a replicatable rna

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957858A (en) * 1986-04-16 1990-09-18 The Salk Instute For Biological Studies Replicative RNA reporter systems
US5451505A (en) * 1989-05-22 1995-09-19 Hoffmann-La Roche Inc. Methods for tagging and tracing materials with nucleic acids
EP0481704A1 (fr) * 1990-10-16 1992-04-22 Ciba Corning Diagnostics Corp. L'amplification de matrices d'ADN de midivariant
US5407798A (en) * 1990-10-16 1995-04-18 Ciba Corning Diagnostics Corp. Amplification of midivariant DNA templates
US5395752A (en) * 1993-03-19 1995-03-07 Ciba Corning Diagnostics Corp. Long emission wavelength chemiluminescent compounds and their use in test assays

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL CHEMISTRY, 1991, Vol. 37, No. 9, CAHILL et al., "Polymerase Chain Reaction and Qbeta Replicase Amplification", pages 1482-1485. *
SCIENCE, 02 October 1992, Vol. 258, SANO et al., "Immuno-PCR: Very Sensitive Antigen Detection by Means of Specific Antibody-DNA Conjugates", pages 120-122. *
TIBTECH, February 1991, Vol. 9, LIZARDI et al., "Exponential Amplification of Nucleic Acids: New Diagnostics Using DNA Polymerases and RNA Replicases", pages 53-58. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0813064A1 (fr) * 1996-06-10 1997-12-17 Bayer Corporation Méthode d'amplification du signal de réponse à un immuno-essai sandwich
DE19959857C1 (de) * 1999-12-10 2001-06-28 Aventis Res & Tech Gmbh & Co Testsystem zum Nachweis von Analyten sowie ein Verfahren zur Herstellung und Verwendung
DE10041766A1 (de) * 2000-08-25 2002-03-14 Friz Biochem Gmbh Verfahren zur Markierung chemischer Substanzen
WO2002016635A3 (fr) * 2000-08-25 2003-06-05 Friz Biochem Gmbh Procede pour le marquage de substances chimiques
GB2375822A (en) * 2000-12-05 2002-11-27 Norchip As Immunoassay using nucleic acid amplification and real-time measurement
GB2375822B (en) * 2000-12-05 2005-04-06 Norchip As Real time ligand detection comprising isothermal amplification
US7910294B2 (en) 2000-12-05 2011-03-22 Norchip A/S Ligand detection method
WO2003048388A3 (fr) * 2001-12-07 2003-09-25 Univ Liverpool Immuno-dosage utilisant l'amplification en chaine de par polymerase
WO2005003394A3 (fr) * 2003-06-27 2005-07-28 Nanosphere Inc Detection d'analytes cible a base de codes a barres biochimiques
WO2006078289A3 (fr) * 2004-05-12 2007-02-08 Nanosphere Inc Detection d'analytes cibles fondee sur des codes a barres biologiques
AU2005325273B2 (en) * 2004-05-12 2009-07-02 Nanosphere, Inc. Bio-barcode based detection of target analytes
WO2022231730A3 (fr) * 2021-03-22 2023-01-26 Northwestern University Stratégie de synthèse pour polymériser une protéine en polymères définis au plan moléculaire

Also Published As

Publication number Publication date
CA2216466A1 (fr) 1996-10-17
EP0819249A1 (fr) 1998-01-21
US6083689A (en) 2000-07-04
AU5850396A (en) 1996-10-30
EP0819249B1 (fr) 2001-10-04
ATE206520T1 (de) 2001-10-15
MX9707635A (es) 1997-12-31
KR19980703574A (ko) 1998-11-05
JPH11503828A (ja) 1999-03-30
DE69615673D1 (de) 2001-11-08
EP0819249A4 (fr) 1999-04-14
PL322650A1 (en) 1998-02-16
BR9604965A (pt) 1998-07-14

Similar Documents

Publication Publication Date Title
EP0819249B1 (fr) Dosages immunologiques de haute precision dans lesquels on utilise des conjugues d'anticorps comprenant des matrices d'adn replicables
US5656731A (en) Nucleic acid-amplified immunoassay probes
US4748111A (en) Nucleic acid-protein conjugate used in immunoassay
EP0611828B1 (fr) Composition pour l'utilisation dans un procédé de test utilisant des séquences polynucléotidiques
EP0481704B1 (fr) L'amplification de matrices d'ADN de midivariant
EP1255861B1 (fr) Procedes et trousses de detection de proximite
AU659798B2 (en) Protein-nucleic acid probes and immunoassays using same
US4824775A (en) Cells labeled with multiple Fluorophores bound to a nucleic acid carrier
EP0163220B1 (fr) Essai d'hybridation d'un acide nucléique au moyen d'anticorps anti-hybrides détectables
EP0625211B1 (fr) Amplification de rapporteurs d'analyse par replication d'une sequence d'acide nucleique
JP2005521410A (ja) 核酸分析試料の検出と定量化のための方法及び組成物
EP0938588A2 (fr) Procede d'amplification de signaux
US20040018495A1 (en) Microparticle based signal amplification for the detection of analytes
EP0892856A1 (fr) Procede d'amplification et de detection d'un fragment d'acide nucleique d'interet
US20090208932A1 (en) Methods Of Detecting An Analyte In A Sample
WO1994026932A1 (fr) Dosage immonologique marque a l'acide nucleique
JPH08205897A (ja) 特異結合検査法およびそれに用いる検査用試薬
EP1098990B1 (fr) Ensemble et technique de dosage immunologique faisant appel a un polynucleotide a polymerase bloquee

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2216466

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2216466

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1019970706978

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/007635

Country of ref document: MX

Ref document number: 1996920100

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 531046

Country of ref document: JP

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1996920100

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970706978

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996920100

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970706978

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载